Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last kr317.50 DKK
Change Today -12.50 / -3.79%
Volume 182.4K
BAVA On Other Exchanges
As of 11:04 AM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

bavarian nordic a/s (BAVA) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/10/15 - kr393.00
52 Week Low
09/2/14 - kr106.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BAVARIAN NORDIC A/S (BAVA)

Related News

No related news articles were found.

bavarian nordic a/s (BAVA) Related Businessweek News

No Related Businessweek News Found

bavarian nordic a/s (BAVA) Details

Bavarian Nordic A/S, a biotechnology company, researches, develops, and manufactures novel cancer immunotherapies and vaccines for infectious diseases. The company markets IMVANEX, a non-replicating smallpox vaccine in Europe, as well as markets under the IMVAMUNE name in Canada. It is developing PROSTVAC, a targeted immunotherapy candidate for the treatment of metastatic castration-resistant prostate cancer, which is in Phase III clinical trials in collaboration with the National Cancer Institute; and CV-301, an active cancer immunotherapy product candidate, which is in Phase II clinical trials to treat colon, breast, and other cancers. The company is also involved in the development of IMVAMUNE, a non-replicating vaccine for the treatment of smallpox that is in Phase III clinical trials in the United States; and IMVAMUNE freeze-dried to treat smallpox in the liquid frozen form, which is in Phase II clinical trials. In addition, it is developing various products to treat infectious diseases that are in preclinical stage, including MVA-BN Anthrax for the treatment of anthrax in humans and animals; MVA-BN Filo vaccine for ebola and marburg; MVA-BN vaccine for selected biological threats, such as foot-and-mouth disease virus and burkholderia; and MVA-BN respiratory syncytial virus vaccine. Further, the company is involved in the development of MVA-BN Brachyury, a novel, active immunotherapy designed to induce a robust T cell immune response against Brachyury, which is in Phase I trial. Bavarian Nordic A/S was founded in 1994 and is headquartered in Kvistgaard, Denmark.

421 Employees
Last Reported Date: 05/5/15
Founded in 1994

bavarian nordic a/s (BAVA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

bavarian nordic a/s (BAVA) Key Developments

Bavarian Nordic A/S Announces Initiation of Phase 2 Study of PROSTVAC in Patients with Localized Prostate Cancer

Bavarian Nordic A/S announced that the first patient has been enrolled in a new phase 2 clinical study of PROSTVAC, the company's active prostate cancer immunotherapy candidate. The study is designed as a randomized, double-blind, placebo- controlled study for men who have localized prostate cancer, and are undergoing active surveillance. These patients are not experiencing symptoms related to their cancer, and are not being treated with other therapies. The study will be conducted across 6 sites, and is designed to enroll 90 patients with the potential to expand up to 150 patients. The primary endpoint of the study is to determine how well PROSTVAC works in eliciting an immune response in patients with prostate cancer that is found only in the prostate and has not yet metastasized. Changes in CD8 and CD4 T cells in tissue adjacent to the tumor and within malignant portion of prostate biopsies will be measured as will changes in PSA. Secondary endpoints include effects of PROSTVAC on changes in PD-L1 expression, PSA doubling time, and change in tumor grade (Gleason score).

Oxford Vaccines Group Initiates a Phase 2 Study of Bavarian Nordic's Ebola Prime-Boost Vaccine Regimen Combining MVA-BN(r) Filo and Janssen's AdVac(r) Technology

Bavarian Nordic A/S announced that the Oxford Vaccines Group has initiated a Phase 2 clinical study of the Ebola prime-boost vaccine regimen that combines Bavarian Nordic's MVA-BN ® Filo vaccine with the Ad26.ZEBOV vaccine from the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). The first volunteers have received their initial vaccine dose. Preliminary data from the first-in-human Phase 1 study, presented by Janssen in May to a U.S. Food & Drug Administration Advisory Committee, indicated that the prime-boost vaccine regimen is immunogenic, regardless of the order of vaccine administration, and only provoked temporary reactions normally expected from vaccination. The Phase 2 study, to take place in the UK and France, is a randomized, placebo-controlled, multicenter trial evaluating the safety, tolerability and immunogenicity of the heterologous prime-boost regimen (Ad26.ZEBOV and MVA-BN-Filo) sponsored by Crucell Holland B.V., one of the Janssen Pharmaceutical Companies. The study is part of the EBOVAC2 project, a collaborative program involving The University of Oxford, French Institute of Health and Medical Research (Inserm), London School of Hygiene & Tropical Medicine (LSHTM), La Centre Muraz (CM), Inserm Transfert (IT) and Janssen. The Innovative Medicines Initiative 2 Joint Undertaking is under grant agreement EBOVAC2 (grant no. 115861), part of the Ebola+ program launched in response to the Ebola virus disease outbreak.

Bavarian Nordic A/S Receives Order for IMVAMUNE Smallpox Vaccine from the U.S. Government

Bavarian Nordic A/S announced that the Biomedical Advanced Research and Development Authority, a division of the U.S. Department of Health & Human Services, has ordered a bulk supply of IMVAMUNE non-replicating smallpox vaccine, valued at USD 133 million. Under this new order, which is an extension of an existing contract, Bavarian Nordic will manufacture and store a bulk supply of IMVAMUNE. This bulk material could be converted into freeze-dried IMVAMUNE at a later date, once the freeze-drying manufacturing process has been transferred to a commercial line, and is approved by the U.S. authorities. The freeze-dried version of IMVAMUNE is expected to reduce the life cycle management costs based on a longer shelf life and will replace the liquid-frozen version that is currently stockpiled in the U.S. Strategic National Stockpile. The freeze-dried version is well positioned to fulfill the U.S. Government's long-term requirements for sufficient non-replicating smallpox vaccine to protect 66 million Americans, comprising those for whom a replicating smallpox vaccine is not recommended and their household contacts. Bavarian Nordic recently reported positive results from a pivotal Phase 2 study, which demonstrated that the freeze-dried and the liquid-frozen versions of the vaccine induced an equivalent immune response in people. With the clinical development now completed, the only outstanding activity to support the stockpiling of this next-generation of the vaccine by the U.S government is the finalization of the transfer of the manufacturing process, which is expected by the end of the year. This bulk vaccine order will be produced and revenue recognized in 2016 and into 2017, and thus does not affect the company's expectations for the financial results for 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAVA:DC kr317.50 DKK -12.50

BAVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Celldex Therapeutics Inc $23.41 USD -0.29
Chimerix Inc $52.91 USD +0.22
Emergent BioSolutions Inc $32.93 USD +0.53
PharmAthene Inc $1.69 USD -0.02
Valneva SE €3.96 EUR +0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation BAVA Industry Range
Price/Earnings 100.0x
Price/Sales 8.1x
Price/Book 7.4x
Price/Cash Flow 134.6x
TEV/Sales 6.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAVARIAN NORDIC A/S, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at